ISIS Neutron and Muon Source Data Journal

Affibody labelled lipid nanoparticles for cancer therapeutics

Abstract: Heralded by their unprecedented success in the Covid-19 vaccines, lipid nanoparticles (LNPs) are revolutionizing RNA medicine. To apply LNP technology to other crucial healthcare questions, e.g. cancer immunotherapy, new LNP formulations are required which can selectively target certain cells in the body. We are addressing this by specifically labelling LNP surfaces with affibodies to target specific cell surface receptors. Affibodies are engineered, robust affinity proteins, which are much smaller than traditionally-used antibodies, and can afford significant surface functionalization without extensively changing the LNP surface. Having already demonstrated targeted uptake of these affibody-LNPs in cells, in this proposal we will quantify the impact of labelling on LNP structure to enable us to understand the relationship between LNP labelling, structure, uptake and function.

Principal Investigator: Dr Hanna Barriga
Experimenter: Dr Margaret Holme
Local Contact: Dr James Doutch
Experimenter: Professor Molly Stevens
Experimenter: Dr Phillip Chivers
Experimenter: Dr Miina Ojansivu
Experimenter: Ms Amy Monahan
Experimenter: Miss Christy Sadler
Experimenter: Miss Lijun Hu
Experimenter: Miss Peiying Liu
Experimenter: Mr Li Ma
Experimenter: Dr David Peeler
Experimenter: Dr Luke Salter

DOI: 10.5286/ISIS.E.RB2220622

ISIS Experiment Number: RB2220622

Publisher: STFC ISIS Neutron and Muon Source

Data format: RAW/Nexus
Select the data format above to find out more about it.

Data Citation

The recommended format for citing this dataset in a research publication is as:
[author], [date], [title], [publisher], [doi]

For Example:
Dr Hanna Barriga et al; (2023): Affibody labelled lipid nanoparticles for cancer therapeutics, STFC ISIS Neutron and Muon Source, https://doi.org/10.5286/ISIS.E.RB2220622

Data is released under the CC-BY-4.0 license.